ORKA · Oruka Therapeutics, Inc. · Insider Trading

The warrant vests as to 1/4 of the underlying shares on April 3, 2025 and as to 1/48 of the underlying shares monthly from April 3, 2025.

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.60 to $92.59, inclusive.

These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 14, 2026.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.28 to $92.27, inclusive.

These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 14, 2026.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $90.27 to $91.26, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this Form 4.

These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 14, 2026.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $92.31 to $92.59, inclusive.

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $90.51 to $91.49, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4.

The warrant vests as to 1/4 of the underlying shares on April 3, 2025 and as to 1/48 of the underlying shares monthly from April 3, 2025.

The option vests as to 1/4 of the underlying shares on August 24, 2027, and vests as to 1/48 of the underlying shares monthly thereafter.

The grant vests as to 1/4 of the shares on September 14, 2027, with the balance vesting in 12 equal quarterly installments thereafter.

The warrant vests as to 1/4 of the underlying shares on April 18, 2025 and as to 1/48 of the underlying shares monthly from April 18, 2025.

These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.34 to $112.86, inclusive.

The option vests as to 1/4 of the underlying shares on April 18, 2025 and as to 1/48 of the underlying shares monthly from April 18, 2025.

These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.34 to $112.33, inclusive.

These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.27 to $111.00, inclusive.

These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.05 to $110.04, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4) and (5) to this Form 4.

The warrant vests as to 1/4 of the underlying shares on April 30, 2025 and as to 1/48 of the underlying shares monthly from April 30, 2025.

These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 15, 2026.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $107.54 to $108.52, inclusive.

These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 15, 2026.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.58 to $110.55, inclusive.

These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 15, 2026.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $106.54 to $107.53, inclusive.

These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 15, 2026.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $105.53 to $106.51, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6) and (7) to this Form 4.

These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 15, 2026.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.66 to $111.22, inclusive.

These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 15, 2026.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.56 to $109.51, inclusive.

The option vests as to 1/48 of the underlying shares monthly from January 1, 2025.

These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 11, 2026.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.24 to $108.71, inclusive.

These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 11, 2026.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $106.11 to $107.07, inclusive.

The option vests as to 1/48 of the underlying shares monthly from January 1, 2025.

The option vests as to 1/48 of the underlying shares monthly from January 1, 2026.

These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 11, 2026.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $104.05 to $104.99, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5) and (6) to this Form 4.

These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 11, 2026.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $107.20 to $108.19, inclusive.

These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 11, 2026.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $105.11 to $106.08, inclusive.

These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.25 to $87.26, inclusive.

The option vests as to 1/4 of the underlying shares on April 18, 2025 and as to 1/48 of the underlying shares monthly from April 18, 2025.

The warrant vests as to 1/4 of the underlying shares on April 18, 2025 and as to 1/48 of the underlying shares monthly from April 18, 2025.

These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.87 to $84.57, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4) and (5) to this Form 4.

These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.21 to $86.20, inclusive.

These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $86.21 to $87.04, inclusive.

These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 11, 2026.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.56 to $85.69, inclusive.

These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 11, 2026.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.54 to $84.53, inclusive.

These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 11, 2026.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.49 to $83.37, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4) and (5) to this Form 4.